Lead Product(s) : Ulipristal Acetate
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Approved FDF
Sponsor : Perrigo Company plc
Deal Size : $2,100.0 million
Deal Type : Acquisition
Perrigo to Acquire Leading Consumer Self-Care Company, HRA Pharma
Details : HRA is one of the fastest growing over-the-counter ("OTC") companies globally, with three category-leading self-care brands in blister care (Compeed®), women's health (ellaOne®) and scar care (Mederma®).
Product Name : ellaOne
Product Type : Other Small Molecule
Upfront Cash : $2,100.0 million
August 09, 2021
Lead Product(s) : Ulipristal Acetate
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Approved FDF
Sponsor : Perrigo Company plc
Deal Size : $2,100.0 million
Deal Type : Acquisition
Reset All
